- List
- By Topic
- On Map
- Search Details

SMA (130 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT00774423 | Completed | Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
141 | All | 6 Years to 20 Years (Child, Adult) | NCT00774423 | P040904 | ASIRI | January 2006 | September 2011 | December 2011 | October 17, 2008 | February 15, 2013 |
|
||
2 | NCT01736553 | Completed Has Results |
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development |
|
Observational |
|
Other / NIH |
|
|
53 | All | up to 6 Months (Child) | NCT01736553 | NN101 U01NS079163 |
December 2012 | September 2015 | September 2015 | November 29, 2012 | May 4, 2018 | May 4, 2018 |
|
||||
3 | NCT03461289 | Recruiting | Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
30 | All | up to 6 Months (Child) | NCT03461289 | AVXS-101-CL-302 | STRIVE-EU | August 29, 2018 | November 2020 | November 2020 | March 12, 2018 | January 31, 2019 |
|
||
4 | NCT02941328 | Completed | SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4 |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
39 | All | 12 Years and older (Child, Adult, Older Adult) | NCT02941328 | NL38048.041.14 | SPACE | December 2015 | January 2018 | January 2018 | October 21, 2016 | February 2, 2018 |
|
||
5 | NCT02876094 | Not yet recruiting | Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
12 | All | 2 Years to 80 Years (Child, Adult, Older Adult) | NCT02876094 | 15/22E | SMA | September 3, 2018 | July 2019 | July 2019 | August 23, 2016 | July 27, 2018 |
|
||
6 | NCT02466529 | Completed | Natural History of Spinal Muscular Atrophy Type 1 in Taiwan |
|
Observational |
|
Other / Industry |
|
|
111 | All | up to 36 Years (Child, Adult) | NCT02466529 | SMA-NHR10311 | June 2015 | December 2015 | December 2015 | June 9, 2015 | June 22, 2017 | ||||||
7 | NCT01862042 | Active, not recruiting | Palliative Care in Spinal Muscular Atrophy (SMA) 1 |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
39 | All | up to 1 Year (Child) | NCT01862042 | AOM 11183 | ASI1 | June 2012 | December 2018 | June 2019 | May 24, 2013 | March 2, 2018 |
|
||
8 | NCT03554343 | Recruiting | Sun May Arise on SMA : Newborn Screening of SMA in Belgium |
|
|
Observational |
|
Other / Industry |
|
|
180000 | All | up to 7 Days (Child) | NCT03554343 | B412201734396 | March 5, 2018 | March 4, 2021 | July 31, 2021 | June 13, 2018 | November 20, 2018 |
|
||||
9 | NCT01645787 | Completed | Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
11 | All | 18 Years to 50 Years (Adult) | NCT01645787 | AAAI7400 | June 2012 | September 2015 | September 2015 | July 20, 2012 | May 18, 2016 |
|
|||
10 | NCT00961103 | Unknown † | Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) |
|
Observational |
|
Other |
|
|
70 | All | Child, Adult, Older Adult | NCT00961103 | UDGEE-SMA | September 2009 | November 2009 | December 2009 | August 18, 2009 | August 18, 2009 |
|
|||||
11 | NCT03520179 | Recruiting | Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA) |
|
Observational |
|
Other |
|
|
70 | All | 3 Months to 99 Years (Child, Adult, Older Adult) | NCT03520179 | 11DN15 | SMA-REACH | December 17, 2013 | January 31, 2019 | January 31, 2019 | May 9, 2018 | May 9, 2018 |
|
||||
12 | NCT01302600 | Completed | Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients. |
|
|
Interventional |
Phase 2 |
|
Industry / Other |
|
|
165 | All | 3 Years to 25 Years (Child, Adult) | NCT01302600 | WN29836 TRO19622 CL E Q 1275-1 |
November 2010 | October 2013 | October 2013 | February 24, 2011 | November 22, 2016 |
|
|||
13 | NCT01611610 | Completed | Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
4 | All | 30 Months to 18 Years (Child, Adult) | NCT01611610 | SMA Europe | May 2011 | May 2013 | May 2013 | June 5, 2012 | March 5, 2014 | ||||
14 | NCT02865109 | Available | Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA) |
|
|
Expanded Access
|
|
Industry | All | Child, Adult, Older Adult | NCT02865109 | 232-SM-901 | August 12, 2016 | October 24, 2018 |
|
||||||||||
15 | NCT02462759 | Completed | A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
21 | All | Child, Adult, Older Adult | NCT02462759 | 232SM202 2014-003657-33 |
EMBRACE | August 19, 2015 | September 24, 2018 | September 24, 2018 | June 4, 2015 | January 16, 2019 |
|
||
16 | NCT01547871 | Terminated | Infants With Spinal Muscular Atrophy Type I |
|
Observational |
|
NIH |
|
|
4 | All | 1 Year to 6 Years (Child) | NCT01547871 | 999912067 12-N-N067 |
February 7, 2012 | April 14, 2016 | March 8, 2012 | February 5, 2019 |
|
||||||
17 | NCT00061607 | Completed | Measuring Levels of SMN in Blood Samples of SMA Patients |
|
Observational |
|
NIH | 73 | All | 2 Years and older (Child, Adult, Older Adult) | NCT00061607 | 030203 03-N-0203 |
May 19, 2003 | April 4, 2017 | May 30, 2003 | October 6, 2017 |
|
||||||||
18 | NCT03300869 | Recruiting | Natural History of Types 2 and 3 SMA in Taiwan |
|
Observational |
|
Other / Industry |
|
|
300 | All | 6 Months to 70 Years (Child, Adult, Older Adult) | NCT03300869 | SMA_RV | September 1, 2017 | December 2019 | December 2019 | October 4, 2017 | November 13, 2017 |
|
|||||
19 | NCT03217578 | Recruiting | Neonatal Spinal Muscular Atrophy (SMA) Screening |
|
|
Observational |
|
Other |
|
|
250000 | All | up to 2 Weeks (Child) | NCT03217578 | SMA-NBS001 | SMA | September 1, 2017 | December 31, 2019 | December 31, 2019 | July 14, 2017 | August 8, 2018 |
|
|||
20 | NCT00661453 | Completed Has Results |
CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
40 | All | up to 12 Months (Child) | NCT00661453 | 25409 IND 79276 |
April 2008 | May 2012 | June 2012 | April 18, 2008 | June 15, 2015 | June 15, 2015 |
|
||
21 | NCT02895789 | Recruiting | Oxidative Capacity and Exercise Tolerance in Ambulatory SMA |
|
Observational |
|
Other / NIH |
|
|
42 | All | 8 Years to 55 Years (Child, Adult) | NCT02895789 | AAAQ9447 1K01HD084690-01A1 |
November 2016 | July 2019 | May 2020 | September 12, 2016 | May 1, 2018 |
|
|||||
22 | NCT02831296 | Recruiting | Prospective Evaluation of Infants With Spinal Muscular Atrophy: |
|
Observational |
|
Other / NIH |
|
|
200 | All | Child, Adult, Older Adult | NCT02831296 | 2015P001934 R01HD069045 |
SPOTSMA | February 2016 | March 2022 | July 13, 2016 | April 19, 2017 |
|
|||||
23 | NCT02268552 | Recruiting | An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
44 | All | up to 182 Days (Child) | NCT02268552 | CLMI070X2201 | April 2, 2015 | July 23, 2020 | July 23, 2020 | October 20, 2014 | February 5, 2019 |
|
|||
24 | NCT01166022 | Completed | Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
14 | All | 8 Years to 50 Years (Child, Adult) | NCT01166022 | AAAE8200 A-15886 |
December 2010 | August 2014 | August 2014 | July 20, 2010 | August 12, 2016 |
|
|||
25 | NCT00227266 | Completed Has Results |
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
94 | All | 2 Years to 17 Years (Child) | NCT00227266 | 13698 | September 2005 | November 2007 | November 2007 | September 27, 2005 | September 26, 2011 | May 3, 2011 |
|
||
26 | NCT02061189 | Active, not recruiting | Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
30 | All | 5 Years to 10 Years (Child) | NCT02061189 | P120124 2013-A01331-44 |
ExerASI | March 2014 | September 2019 | March 2020 | February 12, 2014 | October 12, 2018 |
|
||
27 | NCT02594124 | Active, not recruiting | A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
292 | All | Child, Adult, Older Adult | NCT02594124 | ISIS 396443-CS11 2015-001870-16 |
SHINE | November 4, 2015 | August 29, 2023 | August 29, 2023 | November 2, 2015 | January 30, 2019 |
|
||
28 | NCT02292537 | Completed Has Results |
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
126 | All | 2 Years to 12 Years (Child) | NCT02292537 | ISIS 396443-CS4 2014-001947-18 |
CHERISH | November 24, 2014 | February 20, 2017 | February 20, 2017 | November 17, 2014 | February 21, 2018 | February 21, 2018 |
|
|
29 | NCT01839656 | Completed Has Results |
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
21 | All | up to 210 Days (Child) | NCT01839656 | ISIS 396443-CS3A 2017-000621-12 |
May 8, 2013 | August 21, 2017 | August 21, 2017 | April 25, 2013 | October 30, 2018 | October 30, 2018 |
|
||
30 | NCT02052791 | Completed | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
47 | All | Child, Adult, Older Adult | NCT02052791 | ISIS 396443-CS12 | January 2014 | January 2017 | January 2017 | February 3, 2014 | March 24, 2017 |
|
|||
31 | NCT01494701 | Completed | An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
28 | All | 2 Years to 14 Years (Child) | NCT01494701 | ISIS 396443 - CS1 | SMNRx | November 30, 2011 | January 31, 2013 | January 31, 2013 | December 19, 2011 | April 6, 2017 |
|
||
32 | NCT03505099 | Recruiting | Pre-Symptomatic Study of Intravenous AVXS-101 in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
44 | All | up to 42 Days (Child) | NCT03505099 | AVXS-101-CL-304 2017-004087-35 |
SPR1NT | April 10, 2018 | October 2020 | June 2023 | April 23, 2018 | December 24, 2018 |
|
||
33 | NCT01033331 | Completed | Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy(SMA) Treated With Valproic Acid |
|
Observational |
|
Other |
|
|
22 | All | 2 Years to 18 Years (Child, Adult) | NCT01033331 | 290/06 CAPES9030 |
July 2006 | August 2008 | December 2008 | December 16, 2009 | December 16, 2009 |
|
|||||
34 | NCT03306277 | Active, not recruiting | Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
20 | All | up to 180 Days (Child) | NCT03306277 | AVXS-101-CL-303 | STR1VE | October 24, 2017 | November 30, 2019 | November 30, 2019 | October 11, 2017 | January 24, 2019 |
|
||
35 | NCT02644668 | Completed | A Study of CK-2127107 in Patients With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
70 | All | 12 Years and older (Child, Adult, Older Adult) | NCT02644668 | CY 5021 | December 2015 | May 31, 2018 | May 31, 2018 | January 1, 2016 | August 8, 2018 |
|
|||
36 | NCT03395795 | Recruiting | Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
20 | All | 1 Year to 18 Years (Child, Adult) | NCT03395795 | P160941J IDRCB 2017-A02785-48 |
NAVASI | February 13, 2018 | February 2020 | February 2020 | January 10, 2018 | April 26, 2018 |
|
||
37 | NCT01754441 | Unknown † | Mechanisms of Cell Death in Spinal Muscular Atrophy |
|
Observational |
|
Other |
|
|
50 | All | up to 21 Years (Child, Adult) | NCT01754441 | 82008 | May 2008 | December 2017 | December 2017 | December 21, 2012 | August 24, 2015 |
|
|||||
38 | NCT02123186 | Completed | Newborn Screening for Spinal Muscular Atrophy |
|
|
Observational |
|
Other |
|
|
120267 | All | up to 3 Months (Child) | NCT02123186 | 201308058RIND | October 2013 | October 2016 | October 2016 | April 25, 2014 | November 2, 2016 |
|
||||
39 | NCT03056144 | Terminated | Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
1 | All | 6 Years to 18 Years (Child, Adult) | NCT03056144 | YBPA | August 1, 2017 | July 12, 2018 | July 12, 2018 | February 17, 2017 | October 10, 2018 |
|
|||
40 | NCT03339830 | Recruiting | European Registry of Patients With Infantile-onset Spinal Muscular Atrophy |
|
Observational |
|
Other |
|
|
100 | All | Child, Adult, Older Adult | NCT03339830 | IO-SMA-Registry 2017-A02291-52 |
October 10, 2017 | December 1, 2022 | December 1, 2022 | November 13, 2017 | January 24, 2018 |
|
|||||
41 | NCT03837184 | Not yet recruiting New |
Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
6 | All | up to 6 Months (Child) | NCT03837184 | AVXS-101-CL-306 | February 25, 2019 | March 23, 2021 | March 23, 2021 | February 12, 2019 | February 12, 2019 |
|
|||
42 | NCT02391831 | Completed | Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
81 | All | 2 Years to 30 Years (Child, Adult) | NCT02391831 | NatHis-SMA IDRCB-2014-A01263-44 |
NatHis-SMA | May 2015 | June 2018 | June 2018 | March 18, 2015 | July 19, 2018 |
|
||
43 | NCT00528268 | Completed Has Results |
Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
14 | All | up to 6 Months (Child) | NCT00528268 | 22183 1R01HD054599-01 |
STOPSMA | July 2007 | December 2013 | December 2013 | September 12, 2007 | July 3, 2015 | July 3, 2015 |
|
|
44 | NCT02227823 | Unknown † | Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
20 | All | 6 Years and older (Child, Adult, Older Adult) | NCT02227823 | 1376 | EMOTAS | July 2014 | July 2017 | July 2017 | August 28, 2014 | August 28, 2014 |
|
||
45 | NCT00374075 | Completed | Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
42 | All | 2 Years and older (Child, Adult, Older Adult) | NCT00374075 | 11893 | September 2003 | February 2006 | September 8, 2006 | August 23, 2016 |
|
||||
46 | NCT02003937 | Completed | Aerobic Training in Patients With Spinal Muscular Atrophy Type III |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
15 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02003937 | H-KF297836 | September 2009 | September 2010 | September 2010 | December 6, 2013 | October 29, 2015 |
|
|||
47 | NCT01522079 | Completed | Spinal Muscular Atrophy and Cardiac Autonomic Function |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
9 | All | 5 Years to 25 Years (Child, Adult) | NCT01522079 | Dias | January 2011 | August 2011 | October 2011 | January 31, 2012 | January 31, 2012 | ||||
48 | NCT03648658 | Not yet recruiting | Paracetamol Study in Patients With Low Muscle Mass |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
48 | All | 6 Years to 45 Years (Child, Adult) | NCT03648658 | 08-06-2018-paracet 2018-002295-40 |
August 2018 | July 2021 | July 2021 | August 27, 2018 | August 27, 2018 | ||||
49 | NCT02122952 | Completed | Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
15 | All | up to 6 Months (Child) | NCT02122952 | AVXS-101-CL-101 | May 5, 2014 | December 15, 2017 | December 15, 2017 | April 25, 2014 | February 28, 2018 |
|
|||
50 | NCT00439218 | Terminated Has Results |
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
5 | All | 2 Months to 48 Months (Child) | NCT00439218 | N01NS42361_NPTUNE02 HHSN265200423611C |
NPTUNE 02 | January 2008 | May 2009 | May 2009 | February 23, 2007 | November 9, 2010 | July 20, 2010 |
|
|
51 | NCT00439569 | Terminated Has Results |
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
9 | All | 2 Years to 11 Years (Child) | NCT00439569 | N01NS42361_NPTUNE01 HHSN265200423611C |
NPTUNE01 | January 2008 | August 2008 | August 2008 | February 23, 2007 | September 8, 2010 | February 12, 2010 |
|
|
52 | NCT00481013 | Completed | Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
33 | All | 18 Years to 60 Years (Adult) | NCT00481013 | 2006H0249 | VALIANTSMA | July 2007 | December 2009 | November 2010 | June 1, 2007 | December 6, 2016 |
|
||
53 | NCT01671384 | Unknown † | Valproate and Levocarnitine in Children With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
60 | All | 2 Years to 15 Years (Child) | NCT01671384 | Valproate and SMA | August 2013 | December 2016 | December 2016 | August 23, 2012 | January 1, 2016 |
|
|||
54 | NCT02193074 | Terminated Has Results |
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
122 | All | up to 210 Days (Child) | NCT02193074 | ISIS 396443-CS3B 2013-004422-29 |
ENDEAR | August 19, 2014 | November 21, 2016 | November 21, 2016 | July 17, 2014 | July 28, 2017 | July 28, 2017 |
|
|
55 | NCT01780246 | Completed | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
18 | All | 2 Years to 15 Years (Child) | NCT01780246 | ISIS 396443-CS10 | January 2013 | February 2014 | February 2014 | January 31, 2013 | April 4, 2017 |
|
|||
56 | NCT01703988 | Completed Has Results |
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
34 | All | 2 Years to 15 Years (Child) | NCT01703988 | ISIS 396443 - CS2 2017-000327-27 |
October 2012 | January 2015 | January 2015 | October 11, 2012 | March 13, 2017 | March 13, 2017 |
|
||
57 | NCT03808233 | Completed New |
Reliability and Validity of the ACTIVE-mini for Quantifying Movement in Infants With Spinal Muscular Atrophy |
|
|
Observational |
|
Other |
|
|
25 | All | Child, Adult, Older Adult | NCT03808233 | STU 052016-109 | November 5, 2016 | June 1, 2018 | August 31, 2018 | January 17, 2019 | January 17, 2019 | |||||
58 | NCT00756821 | Completed | A Pilot Study of Biomarkers for Spinal Muscular Atrophy |
|
Observational |
|
Other |
|
|
130 | All | 2 Years to 12 Years (Child) | NCT00756821 | BforSMA | BforSMA | October 2008 | March 2009 | March 2009 | September 22, 2008 | October 24, 2012 |
|
||||
59 | NCT03381729 | Recruiting | Study of Intrathecal Administration of AVXS-101 for Spinal Muscular Atrophy |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
27 | All | 6 Months to 60 Months (Child) | NCT03381729 | AVXS-101-CL-102 | STRONG | December 14, 2017 | September 1, 2020 | September 1, 2020 | December 22, 2017 | February 7, 2019 |
|
||
60 | NCT03032172 | Recruiting | A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
125 | All | 6 Months to 60 Years (Child, Adult) | NCT03032172 | BP39054 2016-004184-39 |
Jewelfish | March 3, 2017 | December 1, 2020 | December 1, 2020 | January 26, 2017 | January 9, 2019 |
|
||
61 | NCT03709784 | Recruiting | Spinraza in Adult Spinal Muscular Atrophy |
|
|
Observational |
|
Other |
|
|
73 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03709784 | 201805187 | SAS | August 16, 2018 | January 30, 2022 | January 30, 2022 | October 17, 2018 | December 14, 2018 |
|
|||
62 | NCT00443066 | Active, not recruiting | Clinical Study of Spinal Muscular Atrophy |
|
Observational |
|
Other |
|
|
120 | All | Child, Adult, Older Adult | NCT00443066 | AAAB1635 CU52029001 |
May 2005 | October 2020 | December 2022 | March 5, 2007 | February 7, 2017 |
|
|||||
63 | NCT02386553 | Active, not recruiting | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
25 | All | up to 6 Weeks (Child) | NCT02386553 | 232SM201 2014-002098-12 |
NURTURE | May 20, 2015 | January 25, 2022 | January 25, 2022 | March 12, 2015 | August 27, 2018 |
|
||
64 | NCT00485511 | Completed | A Trial of Hydroxyurea in Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
All | 4 Years and older (Child, Adult, Older Adult) | NCT00485511 | DOH96-TD-I-111-TM103 | June 2007 | June 2009 | June 2009 | June 13, 2007 | February 15, 2010 |
|
|||||
65 | NCT00155168 | Unknown † | Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System |
|
Observational |
|
Other |
|
500 | All | Child, Adult, Older Adult | NCT00155168 | 9361700452 | April 2004 | September 12, 2005 | September 12, 2005 |
|
||||||||
66 | NCT03223051 | Recruiting | Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
30 | All | 3 Years to 16 Years (Child) | NCT03223051 | 2017-A01017-46 | ExplorASI | September 7, 2017 | September 7, 2017 | September 2020 | July 19, 2017 | January 25, 2018 |
|
||
67 | NCT02073604 | Completed | Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
47 | All | 15 Years to 82 Years (Child, Adult, Older Adult) | NCT02073604 | C13-16 2013-A00616-39 |
MOMIC2 | March 2014 | February 2016 | February 2016 | February 27, 2014 | August 31, 2016 |
|
||
68 | NCT02763865 | Completed Has Results |
A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT02763865 | Pro00033680 | July 2014 | December 2015 | March 21, 2017 | May 5, 2016 | February 15, 2019 | February 15, 2019 | |||
69 | NCT03421977 | Enrolling by invitation | Long-Term Follow-up Study for Patients From AVXS-101-CL-101 |
|
|
Observational |
|
Industry |
|
|
15 | All | Child, Adult, Older Adult | NCT03421977 | AVXS-101-LT-001 | START | August 15, 2017 | December 2033 | December 2033 | February 5, 2018 | February 7, 2019 |
|
|||
70 | NCT02514928 | Recruiting | Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
430 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT02514928 | PCI003 | June 2015 | June 2017 | June 2019 | August 4, 2015 | August 11, 2016 |
|
|||
71 | NCT00533221 | Completed | Pilot Study of Growth Hormon to Treat SMA Typ II and III |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
20 | All | 6 Years to 35 Years (Child, Adult) | NCT00533221 | SMA-GH 2005-002822-78 |
October 2007 | February 2010 | August 2011 | September 21, 2007 | December 18, 2013 |
|
|||
72 | NCT02347475 | Completed | SMA Flow Patterns in Neonatal Transfusion |
|
|
Observational |
|
Other |
|
|
7 | All | up to 6 Months (Child) | NCT02347475 | 14-0312 | SPARTAN | January 2015 | December 2017 | December 2017 | January 27, 2015 | May 3, 2018 |
|
|||
73 | NCT00466349 | Completed | International SMA Patient Registry |
|
Observational |
|
Other |
|
|
3000 | All | Child, Adult, Older Adult | NCT00466349 | 0202-03 | May 1986 | January 2018 | January 2018 | April 27, 2007 | August 7, 2018 |
|
|||||
74 | NCT03329495 | Not yet recruiting | Laparoscopic Right Hemicoloectomy for Right Colon Cancer With a Medial-to-lateral Approach Orientated by SMA or SMV |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
200 | All | 18 Years to 85 Years (Adult, Older Adult) | NCT03329495 | CRSYM201710 | January 2018 | January 2018 | January 2023 | November 6, 2017 | November 6, 2017 |
|
|||
75 | NCT02550691 | Recruiting | Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
311 | All | 18 Years and older (Adult, Older Adult) | NCT02550691 | 2015/092/HP | BADGES | December 2015 | December 2017 | December 2017 | September 15, 2015 | August 30, 2017 |
|
||
76 | NCT02341053 | Active, not recruiting | Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
6 | All | 3 Years to 14 Years (Child) | NCT02341053 | 1411M55281 | September 2015 | December 2019 | December 2019 | January 19, 2015 | July 10, 2018 |
|
|||
77 | NCT02235090 | Withdrawn | Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
0 | All | 5 Years and older (Child, Adult, Older Adult) | NCT02235090 | CSMA-INPN-1 | October 2016 | September 30, 2017 | October 30, 2017 | September 9, 2014 | February 15, 2019 |
|
|||
78 | NCT02628743 | Active, not recruiting | A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
131 | All | Child, Adult, Older Adult | NCT02628743 | BN29854 2015-001589-25 |
January 20, 2016 | May 8, 2021 | May 8, 2021 | December 11, 2015 | October 30, 2018 |
|
|||
79 | NCT03819660 | Enrolling by invitation New |
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
12 | All | 6 Years to 50 Years (Child, Adult) | NCT03819660 | SMA-002 | SMA3 | January 25, 2019 | December 31, 2020 | April 1, 2021 | January 28, 2019 | January 28, 2019 |
|
||
80 | NCT02908685 | Active, not recruiting | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants |
|
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
|
|
219 | All | 2 Years to 25 Years (Child, Adult) | NCT02908685 | BP39055 2016-000750-35 |
SUNFISH | October 20, 2016 | May 31, 2019 | July 12, 2020 | September 21, 2016 | December 10, 2018 |
|
||
81 | NCT02053831 | Completed | GalaFlex Mesh in Facelift |
|
Observational |
|
Industry |
|
|
15 | All | 21 Years and older (Adult, Older Adult) | NCT02053831 | CP-1040 | November 2011 | March 2014 | June 2014 | February 4, 2014 | March 10, 2015 |
|
|||||
82 | NCT01910168 | Completed | A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis |
|
Observational |
|
Industry |
|
|
36 | All | Child, Adult, Older Adult | NCT01910168 | BE29002 | August 2013 | February 2014 | February 2014 | July 29, 2013 | November 2, 2016 |
|
|||||
83 | NCT03781479 | Recruiting | Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
12 | All | 6 Years to 50 Years (Child, Adult) | NCT03781479 | SMA-001 | January 21, 2019 | December 15, 2019 | March 15, 2020 | December 20, 2018 | January 25, 2019 |
|
|||
84 | NCT02044029 | Completed | Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers. |
|
Observational |
|
Industry |
|
|
38 | All | 10 Years and older (Child, Adult, Older Adult) | NCT02044029 | BE29037 | January 2014 | July 2015 | July 2015 | January 23, 2014 | November 2, 2016 |
|
|||||
85 | NCT01059240 | Completed | SMN Copy Number Distribution in Mali, West Africa |
|
Observational |
|
NIH |
|
|
701 | All | 18 Years and older (Adult, Older Adult) | NCT01059240 | 999910033 10-N-N033 |
January 21, 2010 | May 18, 2017 | January 29, 2010 | February 15, 2019 |
|
||||||
86 | NCT01663584 | Withdrawn | Multi-disease Carrier Screening Test Validation |
|
|
Observational |
|
Industry | 0 | All | 18 Years and older (Adult, Older Adult) | NCT01663584 | Natera014 | August 2012 | June 2013 | August 13, 2012 | July 16, 2013 |
|
|||||||
87 | NCT01984957 | Completed | Differential Study of Muscle Transcriptome |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
42 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT01984957 | P110401 | TRANE | January 2013 | January 2015 | January 2015 | November 15, 2013 | March 23, 2015 |
|
||
88 | NCT02855112 | Unknown † | Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
10 | All | 5 Months to 12 Months (Child) | NCT02855112 | 94-01-87-28524 | June 2015 | December 2016 | July 2017 | August 4, 2016 | August 4, 2016 |
|
|||
89 | NCT00568698 | Completed | A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
18 | All | up to 2 Years (Child) | NCT00568698 | SU-11012007-783 78811 |
January 2004 | November 2008 | November 2008 | December 6, 2007 | July 8, 2009 |
|
|||
90 | NCT02633709 | Completed | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
33 | Male | 18 Years to 45 Years (Adult) | NCT02633709 | BP29840 2015-004605-16 |
January 7, 2016 | August 4, 2016 | August 4, 2016 | December 17, 2015 | October 4, 2018 |
|
|||
91 | NCT00568802 | Unknown † | A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
24 | All | 1 Year to 10 Years (Child) | NCT00568802 | SU-11012007-781 79233 |
January 2004 | December 6, 2007 | December 3, 2008 |
|
|||||
92 | NCT01233817 | Completed Has Results |
Progressive Strength Training in Spinal Muscular Atrophy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
12 | All | 5 Years to 21 Years (Child, Adult) | NCT01233817 | 39995 | June 2010 | June 2013 | June 2013 | November 3, 2010 | June 14, 2017 | March 12, 2013 |
|
||
93 | NCT03779334 | Not yet recruiting | A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
25 | All | up to 6 Weeks (Child) | NCT03779334 | BN40703 | Rainbowfish | February 25, 2019 | February 24, 2021 | March 15, 2025 | December 18, 2018 | January 18, 2019 |
|
||
94 | NCT02913482 | Active, not recruiting | Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy |
|
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
|
|
48 | All | 1 Month to 7 Months (Child) | NCT02913482 | BP39056 2016-000778-40 |
FIREFISH | December 24, 2016 | September 2, 2019 | September 1, 2020 | September 23, 2016 | December 5, 2018 |
|
||
95 | NCT02240355 | Terminated | A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
9 | All | up to 55 Years (Child, Adult) | NCT02240355 | BP29420 2014-002246-41 |
November 2014 | July 2015 | July 2015 | September 15, 2014 | December 22, 2016 |
|
|||
96 | NCT03464903 | Enrolling by invitation | Study of ALS Reversals 2: Genetic Analyses |
|
Observational |
|
Other |
|
|
30 | All | Child, Adult, Older Adult | NCT03464903 | Pro00091570 8007 |
StAR2 | June 25, 2018 | March 2019 | March 2019 | March 14, 2018 | February 8, 2019 |
|
||||
97 | NCT01341236 | Completed | Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
41 | All | Child, Adult, Older Adult | NCT01341236 | Feeding VLBW | September 2011 | March 2013 | March 2013 | April 25, 2011 | March 22, 2013 |
|
|||
98 | NCT02227407 | Unknown † | Reciprocating Gait Orthoses for Paraplegia Patients |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
8 | All | Child, Adult, Older Adult | NCT02227407 | 201305047RINC 200703061R |
UPGO | August 2013 | December 2015 | January 2016 | August 28, 2014 | August 28, 2014 |
|
||
99 | NCT00673751 | Unknown † | Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome |
|
|
Interventional |
Not Applicable |
|
Other |
|
8 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT00673751 | H-A-2008-032 | May 7, 2008 | May 7, 2008 |
|
|||||||
100 | NCT03290768 | Active, not recruiting | Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3) |
|
|
Interventional |
Not Applicable |
|
Industry |
|
|
356 | All | 65 Years and older (Older Adult) | NCT03290768 | Pro00022589 | CGM_IRB-3 | September 13, 2017 | August 23, 2019 | December 2027 | September 25, 2017 | September 24, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.